MGTX MeiraGTx Holdings plc

-0.25  -1%
Previous Close 18.75
Open 18.59
Price To Book 7.58
Market Cap 613899079
Shares 33,183,734
Volume 87,148
Short Ratio
Av. Daily Volume 185,709

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated in 2019.
Phase 1/2 data 1H 2019.
Phase 1/2 data 2H 2019.
X-Linked Retinitis Pigmentosa
Phase 1/2 trial to be initiated 2H 2019.
Phase 1/2 data due 2H 2019.

Latest News

  1. MeiraGTx Reports Full Year 2018 Financial Results
  2. Johnson & Johnson Buys Large Stake in MeiraGTx
  3. 10 Stocks For The Gene Therapy Revolution
  4. MeiraGTx to Present at the Barclays Global Healthcare Conference
  5. Why NOW Is the Time to Buy Gene Therapy Stocks
  6. MeiraGTx Announces $80 Million Private Placement of Ordinary Shares
  7. MeiraGTx Appoints Martin Indyk, Ph.D. to Board of Directors
  8. MeiraGTx to Present at the BIO CEO & Investor Conference
  9. MeiraGTx Enters into Strategic Collaboration with Janssen to Develop and Commercialize Gene Therapy Treatments for Inherited Retinal Diseases
  10. Janssen Enters Worldwide Collaboration and License Agreement with MeiraGTx to Develop Gene Therapy Programs for Inherited Retinal Diseases
  11. Do Directors Own MeiraGTx Holdings plc (NASDAQ:MGTX) Shares?
  12. MeiraGTx to Present at the 37th Annual J.P. Morgan Healthcare Conference
  13. MeiraGTx Announces Publication of New Research Identifying Underlying Mechanism of Functional Improvement Seen with AAV-GAD Gene Therapy in Parkinson’s Disease
  14. MeiraGTx Reports Third Quarter 2018 Financial Results and Provides Corporate Update
  15. MeiraGTx Announces Exclusive Licensing Agreement with National Institutes of Health for Gene Therapy Treatment for Sjögren’s Syndrome and Associated Xerostomia or Xerophthalmia
  16. Benzinga Pro's 5 Stocks To Watch Today